Prostatic biopsy after irradiation therapy for prostatic cancer

Area of Science:

• Oncology
• Urology
• Radiotherapy

Background:

• Prostate cancer radiotherapy outcomes require reliable assessment methods.
• Post-treatment monitoring is crucial for detecting recurrence and guiding further management.

Purpose of the Study:

• To evaluate the prognostic significance of routine prostate needle biopsies conducted 6–36 months post-radiotherapy.
• To determine if biopsy results accurately predict treatment success or failure.

Main Methods:

• Analysis of biopsy results in 146 prostate cancer patients post-definitive radiotherapy (radioactive gold seed implantation and external beam irradiation).
• Patients had no evidence of disease at biopsy and received no other therapy before documented recurrence.
• Follow-up averaged 3.9 years post-irradiation.

Main Results:

• 38% (56/146) of patients had positive biopsy results.
• Positive biopsy rates correlated with clinical stage (17% in Stage B1N to 59% in Stage C1).
• Positive biopsy results significantly increased the risk of local recurrence or distant metastases (p < 0.0005).

Conclusions:

• Prostate needle biopsy is an accurate tool for assessing radiotherapy success.
• A positive post-irradiation biopsy has grave prognostic implications, indicating treatment failure.